No Data
MannKind Corporation (NASDAQ:MNKD) Looks Inexpensive But Perhaps Not Attractive Enough
MannKind Corporation's (NASDAQ:MNKD) price-to-sales (or "P/S") ratio of 7.3x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy
Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
Reported Earlier, MannKind's Inhaled Insulin Afrezza Shows Results in 17-Week Study
MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today a
Express News | MannKind Corp: More People Met Glycemic Target of a1C (Less Than 7%) With Afrezza, Few Subjects Worsened Switching From Usual Care to Inhaled Insulin
I Am 102927471 :